SII Blood Index Tracks Autoimmune Disease Activity Across RA, Lupus, and Spondyloarthritis
A simple ratio of platelets, neutrophils, and lymphocytes emerges as a versatile inflammation biomarker across major autoimmune diseases.
Summary
The systemic immune-inflammation index (SII), calculated as platelet count × neutrophil count ÷ lymphocyte count, is emerging as a powerful, low-cost biomarker across autoimmune diseases. In rheumatoid arthritis (RA), elevated SII correlates with disease activity scores, predicts TNF-α inhibitor response, and inversely associates with the anti-aging protein Klotho. In ankylosing spondylitis and psoriatic arthritis, SII tracks disease severity and treatment outcomes. In systemic lupus erythematosus (SLE), SII predicts lupus nephritis, disease flares (AUC up to 0.963), and adverse pregnancy outcomes. SII outperforms traditional markers like CRP and ESR by simultaneously capturing neutrophil-driven inflammation, lymphocyte immune regulation, and platelet-mediated immune activation. Limitations include confounding by infection and malignancy and a lack of standardized cutoff values.
Detailed Summary
Autoimmune diseases affect 7–9% of the global population and impose significant chronic disease burden. Despite therapeutic advances, clinicians still lack biomarkers that are simultaneously accessible, dynamic, and reflective of the complex immune dysregulation underlying conditions like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and spondyloarthritis (SpA). This 2025 mini-review from West China Hospital synthesizes current evidence on the systemic immune-inflammation index (SII) as a versatile biomarker across these conditions.
The SII is calculated as (platelet count × neutrophil count) ÷ lymphocyte count from routine complete blood count data. First introduced in 2014 as a prognostic tool for hepatocellular carcinoma, the SII captures three immunologically meaningful cell populations: neutrophils drive NET formation and tissue destruction; lymphocytes reflect immune regulatory capacity; and platelets actively participate in endothelial dysfunction, cytokine release, and leukocyte recruitment. Their combined ratio offers a window into the systemic balance between pro-inflammatory and immunoregulatory forces.
In RA, multiple studies confirm that SII correlates with DAS28 disease activity scores, with optimal cutoffs ranging from 305.6 to 578.25. Elevated SII independently predicts RA prevalence in population data and ranks among the strongest predictors of TNF-α inhibitor efficacy. Higher SII quartiles also associate with progressively lower serum Klotho levels — a finding that links inflammation to accelerated biological aging. In SLE, SII demonstrates its broadest utility: it predicts lupus nephritis (cutoff ~545.9, independent risk factor), discriminates severe disease flares with AUC up to 0.963, correlates with SLEDAI scores, and in pregnancy, first-trimester SII elevation (cutoff ~1612.6) forecasts adverse maternal-fetal outcomes. Some SLE studies show weaker associations, underscoring context-dependence. In SpA — including ankylosing spondylitis and psoriatic arthritis — SII associates with imaging-confirmed disease severity, BASDAI scores, and biologic treatment response, with cutoffs between 490 and 800.
Compared to CRP and ESR, the SII provides broader immune insights without requiring specialized assays, making it particularly practical in resource-limited settings. The review also notes SII's relevance to vasculitis-related conditions including Behçet's syndrome and Kawasaki disease. Future directions include integration with complementary indices like the systemic inflammatory response index (SIRI), longitudinal validation studies, and multimodal disease monitoring frameworks combining SII with immunophenotyping data.
Key caveats include the absence of standardized cutoff values across studies, confounding by non-autoimmune conditions such as malignancy and infection, and the biological limitation that total lymphocyte counts do not distinguish between regulatory T cells and pro-inflammatory Th17 subsets — nuances that could meaningfully affect interpretation.
Key Findings
- SII cutoffs between 305–578 distinguish active RA from remission and predict TNF-α inhibitor response.
- In SLE, SII achieves AUC up to 0.963 for severe flares and predicts lupus nephritis independently.
- First-trimester SII >1612.6 is significantly elevated in SLE pregnancies with adverse outcomes.
- Higher SII quartiles in RA patients associate with progressively lower anti-aging Klotho protein levels.
- SII outperforms CRP and ESR by simultaneously capturing neutrophil, lymphocyte, and platelet immune dynamics.
Methodology
This is a narrative mini-review published in Frontiers in Immunology (2025) synthesizing evidence from multiple observational and clinical studies across autoimmune disease cohorts. The authors compiled SII cutoff values, AUC diagnostics, and clinical correlations from peer-reviewed studies using standardized complete blood count-derived SII calculations. No meta-analysis or pooled statistical analysis was performed.
Study Limitations
SII cutoff values vary substantially across studies (e.g., 305–1612 across conditions), limiting generalizability without standardized thresholds. Confounding by malignancy, infection, and medications commonly excluded from autoimmune cohorts may inflate SII in clinical practice. Total lymphocyte counts do not distinguish immunosuppressive regulatory T cells from pro-inflammatory Th17 subsets, reducing biological specificity.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.